Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 619 results
Found 619 results.

2006

Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. "Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)." J. Acquir. Immune Defic. Syndr.. 2006;43(3):320-3.
Peters MG, Andersen J, Lynch P, et al. "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127." Hepatology. 2006;44(5):1110-6.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Shafer RW. "Rationale and uses of a public HIV drug-resistance database." J. Infect. Dis.. 2006;194 Suppl 1:S51-8.
Timmermans EC, Tebas P, Ruiter JPN, Wanders RJA, de Ronde A, de Baar MP. "Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy." Clin. Chem.. 2006;52(6):979-87.
Kendall MA, Andersen JW, van der Horst C. "A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207." Contemp Clin Trials. 2006;27(3):287-94.
Swindells S, A DiRienzo G, Wilkin T, et al. "Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression." JAMA. 2006;296(7):806-14.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Clark SA, Shulman NS, Bosch RJ, Mellors JW. "Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors." AIDS. 2006;20(7):981-4.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
Dubé MP, Wu JW, Aberg JA, et al. "Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148." Antivir. Ther. (Lond.). 2006;11(8):1081-9.
Palmer S, Boltz V, Maldarelli F, et al. "Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy." AIDS. 2006;20(5):701-10.
Delahunty T, Bushman L, Fletcher CV. "Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS." J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2006;830(1):6-12.
Yuste E, Sanford HB, Carmody J, et al. "Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma." J. Virol.. 2006;80(6):3030-41.
Liu D, Yu J, Chen H, Reichman R, Wu H, Jin X. "Statistical determination of threshold for cellular division in the CFSE-labeling assay." J. Immunol. Methods. 2006;312(1-2):126-36.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Mrus JM, Schackman BR, Wu AW, et al. "Variations in self-rated health among patients with HIV infection." Qual Life Res. 2006;15(3):503-14.

Pages